EA021615B1 - Цельное интравагинальное кольцо, содержащее прогестерон, и способ изготовления и применения такого кольца - Google Patents
Цельное интравагинальное кольцо, содержащее прогестерон, и способ изготовления и применения такого кольца Download PDFInfo
- Publication number
- EA021615B1 EA021615B1 EA201070919A EA201070919A EA021615B1 EA 021615 B1 EA021615 B1 EA 021615B1 EA 201070919 A EA201070919 A EA 201070919A EA 201070919 A EA201070919 A EA 201070919A EA 021615 B1 EA021615 B1 EA 021615B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- progesterone
- patient
- days
- elastomer
- ring
- Prior art date
Links
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title claims abstract description 457
- 229960003387 progesterone Drugs 0.000 title claims abstract description 224
- 239000000186 progesterone Substances 0.000 title claims abstract description 224
- 238000000034 method Methods 0.000 title claims abstract description 79
- 229920001971 elastomer Polymers 0.000 claims abstract description 96
- 239000000806 elastomer Substances 0.000 claims abstract description 96
- -1 polysiloxane Polymers 0.000 claims abstract description 69
- 229920001296 polysiloxane Polymers 0.000 claims abstract description 67
- 239000002480 mineral oil Substances 0.000 claims abstract description 52
- 235000010446 mineral oil Nutrition 0.000 claims abstract description 52
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 43
- 230000035935 pregnancy Effects 0.000 claims description 41
- 210000004246 corpus luteum Anatomy 0.000 claims description 36
- 208000035475 disorder Diseases 0.000 claims description 35
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 31
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 31
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 31
- 210000001161 mammalian embryo Anatomy 0.000 claims description 25
- 239000008240 homogeneous mixture Substances 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000003431 cross linking reagent Substances 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 229920005645 diorganopolysiloxane polymer Polymers 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 238000004132 cross linking Methods 0.000 claims description 6
- 238000002513 implantation Methods 0.000 claims description 6
- 230000001850 reproductive effect Effects 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 4
- 229920002554 vinyl polymer Polymers 0.000 claims description 4
- 238000012423 maintenance Methods 0.000 claims 1
- 229940044950 vaginal gel Drugs 0.000 description 29
- 239000000029 vaginal gel Substances 0.000 description 29
- 206010046788 Uterine haemorrhage Diseases 0.000 description 27
- 230000003248 secreting effect Effects 0.000 description 25
- 239000000203 mixture Substances 0.000 description 24
- 235000013601 eggs Nutrition 0.000 description 22
- 230000008859 change Effects 0.000 description 20
- 238000012546 transfer Methods 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 19
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 18
- 210000004696 endometrium Anatomy 0.000 description 18
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 229960005309 estradiol Drugs 0.000 description 17
- 229930182833 estradiol Natural products 0.000 description 17
- 239000002245 particle Substances 0.000 description 16
- 206010046901 vaginal discharge Diseases 0.000 description 16
- 238000001574 biopsy Methods 0.000 description 12
- 208000032843 Hemorrhage Diseases 0.000 description 11
- 230000000740 bleeding effect Effects 0.000 description 11
- 210000004291 uterus Anatomy 0.000 description 10
- 239000006213 vaginal ring Substances 0.000 description 10
- 229960001207 micronized progesterone Drugs 0.000 description 9
- 230000009466 transformation Effects 0.000 description 9
- 210000003679 cervix uteri Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000004720 fertilization Effects 0.000 description 8
- 229940044953 vaginal ring Drugs 0.000 description 8
- 208000004998 Abdominal Pain Diseases 0.000 description 7
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 7
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 7
- 206010019233 Headaches Diseases 0.000 description 7
- 210000003756 cervix mucus Anatomy 0.000 description 7
- 230000002357 endometrial effect Effects 0.000 description 7
- 231100000869 headache Toxicity 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 230000000306 recurrent effect Effects 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- 206010028813 Nausea Diseases 0.000 description 6
- 208000035002 Pregnancy of unknown location Diseases 0.000 description 6
- 206010057190 Respiratory tract infections Diseases 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 6
- 230000008693 nausea Effects 0.000 description 6
- 210000001215 vagina Anatomy 0.000 description 6
- 102000009151 Luteinizing Hormone Human genes 0.000 description 5
- 108010073521 Luteinizing Hormone Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000000287 oocyte Anatomy 0.000 description 5
- 230000016087 ovulation Effects 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 238000009597 pregnancy test Methods 0.000 description 5
- 210000002345 respiratory system Anatomy 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 101000935029 Homo sapiens Isovaleryl-CoA dehydrogenase, mitochondrial Proteins 0.000 description 4
- 102100025392 Isovaleryl-CoA dehydrogenase, mitochondrial Human genes 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 229940040129 luteinizing hormone Drugs 0.000 description 4
- 210000003101 oviduct Anatomy 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000004088 simulation Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 208000002881 Colic Diseases 0.000 description 3
- 208000005171 Dysmenorrhea Diseases 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 206010062767 Hypophysitis Diseases 0.000 description 3
- 206010027514 Metrorrhagia Diseases 0.000 description 3
- 208000007101 Muscle Cramp Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 210000003635 pituitary gland Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229940111800 progesterone vaginal gel Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 208000000995 spontaneous abortion Diseases 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 230000036266 weeks of gestation Effects 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 206010008469 Chest discomfort Diseases 0.000 description 2
- 208000035752 Live birth Diseases 0.000 description 2
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 2
- 208000000450 Pelvic Pain Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 2
- 206010062558 Vaginal erosion Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000035606 childbirth Effects 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000000109 continuous material Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000003511 ectopic pregnancy Diseases 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 210000001667 gestational sac Anatomy 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035752 proliferative phase Effects 0.000 description 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229920001187 thermosetting polymer Polymers 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- CEBKHWWANWSNTI-UHFFFAOYSA-N 2-methylbut-3-yn-2-ol Chemical compound CC(C)(O)C#C CEBKHWWANWSNTI-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 206010006242 Breast enlargement Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 1
- 206010014020 Ear pain Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061224 Limb discomfort Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000010195 Onychomycosis Diseases 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000011707 Ovulation disease Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 208000012642 Sexual Trauma Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 206010047786 Vulvovaginal discomfort Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 229920006125 amorphous polymer Polymers 0.000 description 1
- 229940094957 androgens and estrogen Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000011803 breast fibrocystic disease Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000002573 colposcopy Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000016117 decidualization Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000007176 earache Diseases 0.000 description 1
- 230000032692 embryo implantation Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 208000002566 gonadal dysgenesis Diseases 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000009595 pap smear Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000000819 phase cycle Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- RJKFOVLPORLFTN-UHFFFAOYSA-N progesterone acetate Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 RJKFOVLPORLFTN-UHFFFAOYSA-N 0.000 description 1
- 229940077150 progesterone and estrogen Drugs 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 150000003146 progesterones Chemical class 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229920005573 silicon-containing polymer Polymers 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000005882 tinea unguium Diseases 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000004073 vulcanization Methods 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
- A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
- A61F6/14—Contraceptive devices; Pessaries; Applicators therefor for use by females intra-uterine type
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
- A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
- A61F6/08—Pessaries, i.e. devices worn in the vagina to support the uterus, remedy a malposition or prevent conception, e.g. combined with devices protecting against contagion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C45/00—Injection moulding, i.e. forcing the required volume of moulding material through a nozzle into a closed mould; Apparatus therefor
- B29C45/0001—Injection moulding, i.e. forcing the required volume of moulding material through a nozzle into a closed mould; Apparatus therefor characterised by the choice of material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C45/00—Injection moulding, i.e. forcing the required volume of moulding material through a nozzle into a closed mould; Apparatus therefor
- B29C45/17—Component parts, details or accessories; Auxiliary operations
- B29C45/72—Heating or cooling
- B29C45/7207—Heating or cooling of the moulded articles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2083/00—Use of polymers having silicon, with or without sulfur, nitrogen, oxygen, or carbon only, in the main chain, as moulding material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
- B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
- B29K2105/0035—Medical or pharmaceutical agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
- B29L2031/00—Other particular articles
- B29L2031/753—Medical equipment; Accessories therefor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Manufacturing & Machinery (AREA)
- Mechanical Engineering (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Surgical Instruments (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2611508P | 2008-02-04 | 2008-02-04 | |
| US13945408P | 2008-12-19 | 2008-12-19 | |
| PCT/US2009/000672 WO2009099586A2 (en) | 2008-02-04 | 2009-02-03 | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201070919A1 EA201070919A1 (ru) | 2011-04-29 |
| EA021615B1 true EA021615B1 (ru) | 2015-07-30 |
Family
ID=40939073
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201070919A EA021615B1 (ru) | 2008-02-04 | 2009-02-03 | Цельное интравагинальное кольцо, содержащее прогестерон, и способ изготовления и применения такого кольца |
| EA201491815A EA031017B1 (ru) | 2008-02-04 | 2009-02-03 | Способ поддержания или замещения фазы жёлтого тела |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201491815A EA031017B1 (ru) | 2008-02-04 | 2009-02-03 | Способ поддержания или замещения фазы жёлтого тела |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US8580293B2 (enExample) |
| EP (2) | EP2359807B1 (enExample) |
| JP (2) | JP5507467B2 (enExample) |
| KR (3) | KR20100133969A (enExample) |
| CN (2) | CN104146948B (enExample) |
| AR (1) | AR070561A1 (enExample) |
| AU (1) | AU2009210779B2 (enExample) |
| BR (1) | BRPI0905946B8 (enExample) |
| CA (2) | CA2713943C (enExample) |
| CL (1) | CL2009000242A1 (enExample) |
| DK (2) | DK2359807T3 (enExample) |
| EA (2) | EA021615B1 (enExample) |
| ES (2) | ES2645630T3 (enExample) |
| HR (1) | HRP20171319T1 (enExample) |
| HU (1) | HUE035634T2 (enExample) |
| IL (2) | IL207376A (enExample) |
| LT (1) | LT2249757T (enExample) |
| MX (2) | MX385981B (enExample) |
| NZ (3) | NZ596844A (enExample) |
| PL (2) | PL2249757T3 (enExample) |
| PT (2) | PT2359807T (enExample) |
| SG (2) | SG10201605171QA (enExample) |
| SI (2) | SI2359807T1 (enExample) |
| TW (3) | TWI599359B (enExample) |
| WO (1) | WO2009099586A2 (enExample) |
| ZA (2) | ZA201307321B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2249757T (lt) | 2008-02-04 | 2017-09-25 | Ferring B.V. | Vientisi intravaginaliniai žiedai, apimantys progesteroną, ir jų gamybos bei panaudojimo būdai |
| JP2013535992A (ja) * | 2010-06-22 | 2013-09-19 | テバ ウィメンズ ヘルス インコーポレイテッド | 抗コリン作動剤を含む膣内用デバイスおよびそれを作る方法 |
| US8580294B2 (en) | 2010-10-19 | 2013-11-12 | International Partnership For Microbicides | Platinum-catalyzed intravaginal rings |
| EP2641602A1 (en) * | 2012-03-23 | 2013-09-25 | PregLem S.A. | Method for treating gynecological diseases |
| WO2014122563A1 (en) * | 2013-02-08 | 2014-08-14 | Qpharma Ab | An intra vaginal device, and a method of reducing the rate of diffusion of active ingredients in said intra vaginal device |
| CN103394127A (zh) * | 2013-08-02 | 2013-11-20 | 苏州市马尔泰新材料有限公司 | 一种含有中西医药的阴道模具材料 |
| CN103431930A (zh) * | 2013-08-02 | 2013-12-11 | 苏州市马尔泰新材料有限公司 | 一种含有甲酯树脂的阴道模具 |
| CN103394128A (zh) * | 2013-08-02 | 2013-11-20 | 苏州市马尔泰新材料有限公司 | 一种含有川芎的模具材料 |
| CN103405810A (zh) * | 2013-08-02 | 2013-11-27 | 苏州市马尔泰新材料有限公司 | 一种含有甲基丙烯酸甲酯树脂的阴道模具 |
| CN103445892A (zh) * | 2013-08-02 | 2013-12-18 | 苏州市马尔泰新材料有限公司 | 一种含有甲酯树脂和雌酚的阴道模具 |
| US10137031B2 (en) | 2013-11-14 | 2018-11-27 | International Partnership For Microbicides, Inc. | Combination therapy intravaginal rings |
| CN112494195A (zh) | 2014-04-01 | 2021-03-16 | 保利医学公司 | 避孕装置及相关装置 |
| ES2699003T3 (es) * | 2014-06-28 | 2019-02-06 | Laboratorios Andromaco S A | Pesario de cerclaje que contiene progesterona de liberación prolongada, sostenida y continua, usado para la prevención de partos prematuros |
| CN104546267B (zh) * | 2015-01-13 | 2017-01-04 | 安徽农业大学 | 一种犬用宫外节育装置及其节育方法 |
| BR112018012744A2 (pt) * | 2015-12-21 | 2018-12-04 | Bayer Oy | método de fabricação de um anel vaginal |
| EP3542786A1 (en) * | 2018-03-21 | 2019-09-25 | ITF Research Pharma, S.L.U. | Progesterone intravaginal devices |
| CN114126710A (zh) * | 2019-03-29 | 2022-03-01 | B·马特尔 | 含有孕酮的eva分段式阴道内环 |
| US10918649B2 (en) | 2019-06-21 | 2021-02-16 | The Population Council, Inc. | System for providing birth control |
| US11439588B2 (en) * | 2019-10-12 | 2022-09-13 | National Research Institute For Family Planning | Vaginal sustained-release drug delivery system for luteal support, method for preparation and use thereof |
| TWI791347B (zh) * | 2020-12-11 | 2023-02-01 | 酷氏基因生物科技股份有限公司 | 一種用於評估胚胎植入成功率的預測方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5188835A (en) * | 1986-06-16 | 1993-02-23 | Kabi Pharmacia Ab | Intravaginal devices |
| US5340585A (en) * | 1991-04-12 | 1994-08-23 | University Of Southern California | Method and formulations for use in treating benign gynecological disorders |
| US5869081A (en) * | 1996-06-28 | 1999-02-09 | The Population Council | Progesterone vaginal ring for treatment of infertility |
| US6416780B1 (en) * | 1997-05-07 | 2002-07-09 | Galen (Chemicals) Limited | Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors |
| US20050255157A1 (en) * | 2004-05-11 | 2005-11-17 | Glenmark Pharmaceuticals Limited | Sustained release, mucoadhesive vaginal pharmaceutical compositions |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE494972A (enExample) | 1949-04-07 | |||
| US2863846A (en) | 1950-05-04 | 1958-12-09 | Dow Corning | Organo silyl-silica filled siloxane elastomers and process for producing same |
| US2890188A (en) | 1951-12-17 | 1959-06-09 | Dow Corning | Siloxane elastomers compounded with hydroxylated silanes |
| NL91756C (enExample) | 1953-11-19 | |||
| US3022951A (en) | 1957-05-14 | 1962-02-27 | Ibm | Full adder |
| US3545439A (en) | 1968-01-04 | 1970-12-08 | Upjohn Co | Medicated devices and methods |
| US3948262A (en) * | 1969-04-01 | 1976-04-06 | Alza Corporation | Novel drug delivery device |
| US3854480A (en) * | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| IL48277A (en) * | 1974-10-18 | 1978-03-10 | Schering Ag | Vaginal ring |
| DE3040978A1 (de) * | 1980-10-28 | 1982-05-27 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Vaginalring |
| US4629449A (en) * | 1982-07-29 | 1986-12-16 | Alza Corporation | Vaginal dispenser for dispensing beneficial hormone |
| US4816257A (en) * | 1985-09-20 | 1989-03-28 | Research & Education Institute, Harbor-Ucla Medical Center Inc. | Method for producing an in vivo environment suitable for human embryo transfer |
| SE8602666D0 (sv) * | 1986-06-16 | 1986-06-16 | Leo Ab | Intravaginal devices |
| FR2618329B1 (fr) | 1987-07-22 | 1997-03-28 | Dow Corning Sa | Procede de fabrication d'un anneau capable d'assurer la liberation d'un agent therapeutique, et anneau fabrique par ce procede |
| US5116619A (en) * | 1988-08-30 | 1992-05-26 | Lee Roy Morgan | Vaginal progesterone tablet |
| US5084277A (en) * | 1988-08-30 | 1992-01-28 | Greco John C | Vaginal progesterone tablet |
| DE3838815A1 (de) * | 1988-11-17 | 1990-05-23 | Hoechst Ag | Verfahren zum herstellen eines intravaginalen applikationssystems |
| US6264638B1 (en) * | 1989-12-07 | 2001-07-24 | Ultrafem, Inc. | Intravaginal drug delivery system and discharge collection device |
| US5393528A (en) * | 1992-05-07 | 1995-02-28 | Staab; Robert J. | Dissolvable device for contraception or delivery of medication |
| IT1256393B (it) | 1992-11-17 | 1995-12-04 | Inverni Della Beffa Spa | Forme matriciali multistrato per il rilascio controllato di principi attivi |
| FI95768C (fi) * | 1993-06-17 | 1996-03-25 | Leiras Oy | Emättimensisäinen antosysteemi |
| US5543150A (en) * | 1993-09-15 | 1996-08-06 | Columbia Laboratories, Inc. | Method of progesterone delivery and affect thereof |
| US6586006B2 (en) * | 1994-08-04 | 2003-07-01 | Elan Drug Delivery Limited | Solid delivery systems for controlled release of molecules incorporated therein and methods of making same |
| EP0836473B1 (en) * | 1995-07-04 | 2001-10-31 | Akzo Nobel N.V. | Ring-shaped devices |
| GB9522403D0 (en) * | 1995-11-01 | 1996-01-03 | Hoechst Roussel Ltd | Intravaginal drug delivery device |
| US5744463A (en) * | 1996-06-03 | 1998-04-28 | Bair; Glenn O. | Treatment of side effects of progestins and progesterone analogues used for birth control |
| US5972372A (en) * | 1996-07-31 | 1999-10-26 | The Population Council, Inc. | Intravaginal rings with insertable drug-containing core |
| US6028064A (en) * | 1996-09-13 | 2000-02-22 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of progestin products |
| US5985861A (en) * | 1996-11-04 | 1999-11-16 | Columbia Laboratories, Inc. | Progesterone for treating or reducing ischemia |
| US5814329A (en) * | 1996-11-12 | 1998-09-29 | Polytherapeutics, Inc. | Hydrophilic polystyrene graft copolymer vehicle for intravaginal administration of pharmacologically active agents |
| US6416778B1 (en) * | 1997-01-24 | 2002-07-09 | Femmepharma | Pharmaceutical preparations and methods for their regional administration |
| US5993856A (en) * | 1997-01-24 | 1999-11-30 | Femmepharma | Pharmaceutical preparations and methods for their administration |
| US6056972A (en) * | 1997-02-26 | 2000-05-02 | Dimera, Llc | Method for reducing coronary artery reactivity |
| US6197327B1 (en) * | 1997-06-11 | 2001-03-06 | Umd, Inc. | Device and method for treatment of dysmenorrhea |
| US6039968A (en) | 1997-06-24 | 2000-03-21 | Hoechst Marion Roussel | Intravaginal drug delivery device |
| US6245757B1 (en) * | 1997-10-03 | 2001-06-12 | Research Corporation Technologies, Inc. | Use of progestins to treat ischemic event |
| US6306914B1 (en) * | 1997-10-21 | 2001-10-23 | Columbia Laboratories, Inc. | Progestin therapy for maintaining amenorrhea |
| NZ330596A (en) * | 1998-06-05 | 2001-02-23 | Dec Res | Intravaginal devices allowing for increased uptake of active ingredients |
| AU748653B2 (en) * | 1998-05-01 | 2002-06-06 | John F. Cline | Method for injection molding manufacture of controlled release devices |
| JP2002518351A (ja) | 1998-06-19 | 2002-06-25 | オキシバイオ・インコーポレイテッド | 抗感染および避妊特性を有する医療装置 |
| US7001609B1 (en) * | 1998-10-02 | 2006-02-21 | Regents Of The University Of Minnesota | Mucosal originated drug delivery systems and animal applications |
| US6056976A (en) | 1998-11-12 | 2000-05-02 | Leiras Oy | Elastomer, its preparation and use |
| US6063395A (en) | 1998-11-12 | 2000-05-16 | Leiras Oy | Drug delivery device especially for the delivery of progestins and estrogens |
| US20050197651A1 (en) * | 2001-04-25 | 2005-09-08 | Chen Hai L. | Vaginal ring preparation and its application |
| CN1210079C (zh) * | 2001-04-25 | 2005-07-13 | 上海市计划生育科学研究所 | 阴道环制剂及其应用 |
| AU2002313517B2 (en) * | 2001-08-31 | 2007-09-06 | Bayer Schering Pharma Oy | Drug delivery system |
| AU2003208679A1 (en) * | 2002-02-08 | 2003-09-02 | Advanced Animal Technology Limited | Control of a biological function |
| EP1494646B2 (en) * | 2002-03-27 | 2017-10-04 | Warner Chilcott (Ireland) Limited | Intravaginal matrix drug delivery devices |
| CA2504283A1 (en) * | 2002-10-31 | 2004-05-21 | Umd, Inc. | Therapeutic compositions for drug delivery to and through covering epithelia |
| US20040089308A1 (en) * | 2002-11-13 | 2004-05-13 | Welch Robert A. | Cervical ring to deliver medication |
| FR2849380A1 (fr) * | 2002-12-27 | 2004-07-02 | Ernest Loumaye | NOUVELLE UTILISATION D'UN AGONISTE DU GnRH |
| ATE461681T1 (de) * | 2003-04-29 | 2010-04-15 | Gen Hospital Corp | Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln |
| US8404272B2 (en) * | 2003-06-26 | 2013-03-26 | Poly-Med, Inc. | Fiber-reinforced composite rings for intravaginal controlled drug delivery |
| CA2531640C (en) * | 2003-07-10 | 2013-06-18 | Galen (Chemicals) Limited | Intravaginal drug delivery devices |
| US7707169B2 (en) | 2004-06-10 | 2010-04-27 | Siemens Corporation | Specification-based automation methods for medical content extraction, data aggregation and enrichment |
| KR101229701B1 (ko) * | 2004-07-09 | 2013-02-05 | 라보라토이레 에이치알에이 파르마 | 프로게스테론 수용체 조절제를 함유하는 서방형 조성물 |
| AR043476A1 (es) * | 2004-09-09 | 2005-08-03 | Dvoskin Victor Oscar | Dispositivo de administracion regulada de sustancias para la insercion en una cavidad corporal y procedimiento para fabricar un medio de soporte de dichas sustancias |
| US7517914B2 (en) * | 2005-04-04 | 2009-04-14 | Boston Scientificscimed, Inc. | Controlled degradation materials for therapeutic agent delivery |
| US8399012B2 (en) * | 2006-04-17 | 2013-03-19 | Kimberly-Clark Worldwide, Inc. | Degradable therapeutic delivery device |
| JP2009536164A (ja) * | 2006-05-10 | 2009-10-08 | エボニック デグサ ゲーエムベーハー | ロール圧密成形した熱分解法二酸化ケイ素の医薬組成物での使用 |
| US8828981B2 (en) * | 2007-02-06 | 2014-09-09 | George Creasy | Progesterone for the treatment or prevention of spontaneous preterm birth |
| US20080214512A1 (en) * | 2007-03-01 | 2008-09-04 | Christian Seitz | Pharmaceutical preparation containing a gestagen, and kit and method for treating endometriosis using the preparation |
| CA2823407C (en) * | 2007-03-22 | 2016-10-18 | Berg Pharma Llc | Topical formulations having enhanced bioavailability |
| WO2008140794A1 (en) | 2007-05-11 | 2008-11-20 | The Texas A & M University System | Hormone normalization therapy and uses thereof |
| LT2249757T (lt) | 2008-02-04 | 2017-09-25 | Ferring B.V. | Vientisi intravaginaliniai žiedai, apimantys progesteroną, ir jų gamybos bei panaudojimo būdai |
-
2009
- 2009-02-03 LT LTEP09707504.8T patent/LT2249757T/lt unknown
- 2009-02-03 PT PT101876860T patent/PT2359807T/pt unknown
- 2009-02-03 NZ NZ596844A patent/NZ596844A/en not_active IP Right Cessation
- 2009-02-03 CA CA2713943A patent/CA2713943C/en active Active
- 2009-02-03 CA CA3016642A patent/CA3016642A1/en not_active Abandoned
- 2009-02-03 BR BRPI0905946A patent/BRPI0905946B8/pt not_active IP Right Cessation
- 2009-02-03 NZ NZ61126809A patent/NZ611268A/en not_active IP Right Cessation
- 2009-02-03 SI SI200931723T patent/SI2359807T1/sl unknown
- 2009-02-03 CN CN201410380175.XA patent/CN104146948B/zh active Active
- 2009-02-03 ES ES09707504.8T patent/ES2645630T3/es active Active
- 2009-02-03 CN CN200980112513.9A patent/CN102098991B/zh active Active
- 2009-02-03 US US12/364,990 patent/US8580293B2/en active Active
- 2009-02-03 MX MX2016003140A patent/MX385981B/es unknown
- 2009-02-03 AU AU2009210779A patent/AU2009210779B2/en active Active
- 2009-02-03 KR KR1020107019899A patent/KR20100133969A/ko not_active Ceased
- 2009-02-03 WO PCT/US2009/000672 patent/WO2009099586A2/en not_active Ceased
- 2009-02-03 HR HRP20171319TT patent/HRP20171319T1/hr unknown
- 2009-02-03 DK DK10187686.0T patent/DK2359807T3/en active
- 2009-02-03 DK DK09707504.8T patent/DK2249757T3/en active
- 2009-02-03 MX MX2010008545A patent/MX337634B/es active IP Right Grant
- 2009-02-03 PL PL09707504T patent/PL2249757T3/pl unknown
- 2009-02-03 SG SG10201605171QA patent/SG10201605171QA/en unknown
- 2009-02-03 KR KR1020167012312A patent/KR101730517B1/ko active Active
- 2009-02-03 JP JP2010545030A patent/JP5507467B2/ja active Active
- 2009-02-03 PT PT97075048T patent/PT2249757T/pt unknown
- 2009-02-03 ES ES10187686.0T patent/ES2648640T3/es active Active
- 2009-02-03 SG SG2013008289A patent/SG187529A1/en unknown
- 2009-02-03 HU HUE09707504A patent/HUE035634T2/en unknown
- 2009-02-03 EA EA201070919A patent/EA021615B1/ru unknown
- 2009-02-03 PL PL10187686T patent/PL2359807T3/pl unknown
- 2009-02-03 NZ NZ587758A patent/NZ587758A/en unknown
- 2009-02-03 EA EA201491815A patent/EA031017B1/ru unknown
- 2009-02-03 SI SI200931722T patent/SI2249757T1/sl unknown
- 2009-02-03 EP EP10187686.0A patent/EP2359807B1/en active Active
- 2009-02-03 KR KR1020147006224A patent/KR20140048321A/ko not_active Ceased
- 2009-02-03 EP EP09707504.8A patent/EP2249757B1/en active Active
- 2009-02-04 TW TW104111334A patent/TWI599359B/zh not_active IP Right Cessation
- 2009-02-04 TW TW105113785A patent/TWI655947B/zh active
- 2009-02-04 CL CL2009000242A patent/CL2009000242A1/es unknown
- 2009-02-04 AR ARP090100365A patent/AR070561A1/es not_active Application Discontinuation
- 2009-02-04 TW TW098103540A patent/TWI549681B/zh not_active IP Right Cessation
-
2010
- 2010-08-03 IL IL207376A patent/IL207376A/en active IP Right Grant
-
2012
- 2012-09-19 IL IL221988A patent/IL221988A/en active IP Right Grant
-
2013
- 2013-10-01 ZA ZA2013/07321A patent/ZA201307321B/en unknown
- 2013-10-01 ZA ZA2013/07320A patent/ZA201307320B/en unknown
- 2013-10-03 US US14/045,311 patent/US10548904B2/en active Active
-
2014
- 2014-03-19 JP JP2014055994A patent/JP6124411B2/ja active Active
-
2016
- 2016-06-08 US US15/176,169 patent/US10537584B2/en active Active
-
2020
- 2020-01-31 US US16/778,526 patent/US11413294B2/en active Active
-
2022
- 2022-07-05 US US17/857,959 patent/US20230158044A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5188835A (en) * | 1986-06-16 | 1993-02-23 | Kabi Pharmacia Ab | Intravaginal devices |
| US5340585A (en) * | 1991-04-12 | 1994-08-23 | University Of Southern California | Method and formulations for use in treating benign gynecological disorders |
| US5869081A (en) * | 1996-06-28 | 1999-02-09 | The Population Council | Progesterone vaginal ring for treatment of infertility |
| US6416780B1 (en) * | 1997-05-07 | 2002-07-09 | Galen (Chemicals) Limited | Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors |
| US20050255157A1 (en) * | 2004-05-11 | 2005-11-17 | Glenmark Pharmaceuticals Limited | Sustained release, mucoadhesive vaginal pharmaceutical compositions |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230158044A1 (en) | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof | |
| AU2016202114B2 (en) | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof | |
| AU2013203779B2 (en) | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof | |
| HK1150428B (en) | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof | |
| HK1150428A (en) | Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC4A | Registration of transfer of a eurasian patent by assignment |